IPP Bureau
Bayer and Mammoth Biosciences to collaborate on gene editing technology
By IPP Bureau - January 10, 2022
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics
By IPP Bureau - January 10, 2022
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Novavax and Serum file EUA for Covovax in South Africa
By IPP Bureau - January 10, 2022
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Indica Labs receive CE Mark for its HALO AP
By IPP Bureau - January 10, 2022
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Covaxin booster dose study shows promising results
By IPP Bureau - January 08, 2022
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Moderna Covid-19 boosters after five-month interval: U.S. FDA
By IPP Bureau - January 08, 2022
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine
By IPP Bureau - January 08, 2022
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra
By IPP Bureau - January 07, 2022
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
By IPP Bureau - January 07, 2022
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
By IPP Bureau - January 07, 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron
By IPP Bureau - January 07, 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
Lupin launches Molnulup to treat Covid-19
By IPP Bureau - January 07, 2022
The drug is priced at Rs 2000 for a course of 40 tablets
Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
By IPP Bureau - January 07, 2022
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
AstraZeneca and Neurimmune to develop and commercialise NI006
By IPP Bureau - January 07, 2022
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
By IPP Bureau - January 07, 2022
The transaction is expected to close in the first quarter of 2022
